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Abstract
Background: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and
safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
(TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was designed to provide everolimus
access to patients with SEGA associated with TSC and to mainly assess the safety and also efficacy of everolimus in
a real-world setting.
Methods: EFFECTS was a phase 3b, open-label, noncomparative, multicenter, expanded access study. Eligible
patients were ≥ 3 years of age, with a definite diagnosis of TSC, and with at least one SEGA lesion identified by MRI
or CT scan. Patients received once daily everolimus (dose adjusted to attain a trough level of 5-15 ng/mL). Safety
evaluation was the primary objective and included collection of adverse events (AEs) and serious AEs, with their
severity and relationship to everolimus. Efficacy evaluation, which was the secondary objective, was based on the
best overall response as per medical judgment.
Results: Of the 120 patients enrolled, 100 (83.3 %) completed the study. Median age of patients was 11 years (range,
1-47). Median daily dose of everolimus was 5.82 mg (range, 2.0–11.8). Median duration of exposure was 56.5 weeks
(range, 0.3–130). The overall incidence of AEs was 74.2 %. Aphthous stomatitis (18 [15.0 %]), pyrexia (18 [15.0 %]),
bronchitis (11 [9.2 %]), and stomatitis (10 [8.3 %]) were the most common AEs reported. Overall, 25 patients had grade
3 AEs; most frequent was stomatitis (4 [3.3 %]). Grade 4 AEs were reported in three (2.5 %) patients. A total of 62 (51.
7 %) patients had suspected drug-related AEs, of which 15 (12.5 %) were of grade 3 or 4. In eight (6.7 %) patients, AEs
led to drug discontinuation. With regard to efficacy, 81 (67.5 %) patients had a partial response, 35 (29.2 %) had a stable
disease, and one (0.8 %) had progressive disease. The response was unknown in three (2.5 %) patients.
Conclusion: This study confirms the acceptable safety profile of everolimus in patients with SEGA associated with TSC
in a real-world setting. The results further support the efficacy of everolimus in the treatment of SEGA associated with
TSC. (EudraCT: 2010-022583-13)
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Background
Tuberous sclerosis complex (TSC) is a genetic disorder
that is associated with the development of benign tumors
in multiple organs throughout the body [1–3]. The birth
incidence of TSC is about one in 6000 individuals [2].
Although any organ system can be affected, organs com-
monly involved include the brain, kidneys, skin, lungs,
heart, eyes, and liver. Patients may present with varied
manifestations depending on the organs involved [1–3].
TSC is diagnosed based on the presence of certain major
and minor criteria. The criteria for diagnosis have been re-
cently revised at the 2012 International TSC Consensus
Conference [4].
The brain is the most commonly affected organ in
patients with TSC [5]. Most common brain lesions in-
clude cortical and subcortical tubers, subependymal
nodules, and subependymal giant cell astrocytomas
(SEGAs) [1–3]. SEGAs usually develop in childhood
or adolescence and are seen in up to 20 % of the pa-
tients with TSC. These tumors are generally located
near the foramen of Monro [5]. Although SEGAs usu-
ally grow slowly, they have the potential to enlarge
enough to cause life-threatening complications includ-
ing raised intracranial pressure and hydrocephalus [1,
6]. Until recently, surgery was the only option avail-
able for the treatment of SEGAs. Surgery can be chal-
lenging due to the typical deep location of these
lesions. Surgery is also associated with significant
morbidity and the incompletely resected SEGAs tend
to regrow. In addition, some lesions may not be amen-
able to surgery [6, 7]. In a study that analyzed 64
SEGA surgeries, risk factors for poor outcome in-
cluded bilateral tumors, tumors bigger than 2 cm, and
children younger than 3 years [8].
TSC is most often caused by mutations in either TSC1
(hamartin) or TSC2 (tuberin) gene. Normally, the activation
of mammalian target of rapamycin (mTOR) complex 1,
which is responsible for cell growth, proliferation, and pro-
tein synthesis, is limited by the hamartin-tuberin tumor
suppressor complex. Mutations in either TSC1 or TSC2
gene lead to constitutive activation of the mTOR complex
1, which in turn leads to development of the hamartoma-
tous lesions seen in patients with TSC [1–4]. Based on this
pathophysiological finding, mTOR blockade was explored
as a treatment approach for TSC [9, 10]. Everolimus, an
mTOR inhibitor, has been evaluated for the treatment of
SEGA associated with TSC. In an open-label, phase 1–2
study, everolimus demonstrated significant reduction in the
volume of SEGA associated with TSC [10]. The efficacy
and safety of everolimus in the treatment of SEGA associ-
ated with TSC were confirmed in the randomized, double-
blind, phase 3 study — EXamining everolimus In a Study
of Tuberous sclerosis complex (EXIST-1) [11]. Based on
these results, everolimus was approved by the United States
Food and Drug Administration (USFDA; initial accelerated
approval in 2010) and European Medicines Agency (EMA;
in 2011) for pediatric and adult patients with SEGA associ-
ated with TSC [12, 13].
The process of approval had just begun in several
European countries when the Everolimus For Fast
Expanded aCcess in TSC SEGA (EFFECTS) study
was initiated. The purpose of the study was to pro-
vide access to everolimus prior to commercial avail-
ability in the participating countries and also to
further assess the safety and efficacy of everolimus
in patients with SEGA associated with TSC.
Methods
Study design and patients
EFFECTS was a phase 3b, open-label, noncomparative,
multinational, expanded access study of everolimus for
the treatment of patients with SEGA associated with
TSC. Eligible patients, who were 3 years of age or older,
had a definite diagnosis of TSC (as per the modified
Gomez criteria) [14], and they had at least one SEGA le-
sion identified by magnetic resonance imaging (MRI) or
computed tomography (CT) scan (according to local re-
quirements by size and/or location). Patients had to be
medically stable, with no need of SEGA-related surgery,
with no use of an investigational study drug within
30 days prior to enrollment, and they should not have
participated in the EXIST-1 study [11]. Written in-
formed consent was obtained from all patients (or their
legal representatives) before enrollment. The protocol
was approved by an ethics committee at each center, be-
fore the first patient was enrolled. The study was con-
ducted in accordance with the principles of Good
Clinical Practice, Declaration of Helsinki (2013 version)
[15], and all local regulations.
Treatment
Everolimus was administered as a once-daily oral dose.
Starting dose of everolimus was determined by body sur-
face area (BSA). Recommended starting dose was 2.5 mg
for BSA ≤ 1.2 m2, 5 mg for BSA 1.3 to 2.1 m2, and
7.5 mg for BSA ≥ 2.2 m2. The dose was titrated upward
to attain a trough level in the range 5 to 15 ng/mL. Pa-
tients were asked to visit the clinic every 2 weeks until
the level of everolimus was within the required range of
5 to 15 ng/mL. After stable blood levels of everolimus
were reached, patients visited the clinic monthly. The
treatment was continued until one of the following con-
ditions occurred: tumor progression (determined by
MRI or CT scan); unacceptable toxicity (according to in-
vestigators’ medical judgment); death; discontinuation
from the study for any other reason; or until the drug
became commercially available for SEGA associated with
TSC in the respective countries or up to December 31,
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2013, whichever occurred earlier. In case the drug was
not available in a country as of December 31, 2013, pa-
tients were moved to a local transition plan to ensure
access to the study medication without any delay in the
treatment.
Assessments
Safety assessment
The primary objective of the study was to evaluate the
safety of everolimus in patients with SEGA associated
with TSC. Adverse events (AEs) were monitored con-
tinuously throughout the duration of the study. Grade 3
and 4 AEs, serious AEs (SAEs), and laboratory abnor-
malities were assessed according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) version
4.0 [16]. Grade 1 or 2 AEs and laboratory or test proced-
ure abnormalities were not reported unless they were
clinically significant for the investigator or caused evero-
limus dose modification or interruption because when
compared to standard clinical trials, expanded access
program follows a simplified data collection focusing on
“key safety aspects”, but beyond only SAE. Each AE was
evaluated to determine the following: its severity, its re-
lationship to study drug, its duration, action taken, and
whether it was serious. Monitoring of AEs was contin-
ued for 4 weeks following the last dose of study
treatment.
Efficacy assessment
Efficacy was evaluated as a secondary objective. Tumor
response and progression were assessed using MRI or
CT scans of the brain (volume measurements of SEGA),
at the investigators’ discretion. Tumor assessments were
performed during screening, at 3, 6, and 12 months, and
annually thereafter, as well as at the end of treatment.
The overall investigator assessment of best response was
collected at the end of the study for the FAS population
defined as best radiological and clinical response (radio-
logical response in context with toxicities or other med-
ical observations of the investigator).
Pharmacokinetics assessment
The trough (predose) everolimus blood levels were eval-
uated for all patients at week 2. In addition, trough
blood levels were assessed 1 to 2 weeks after the occur-
rence of any of the following: increase in the dose of
everolimus; reduction in the dose of a CYP3A4 or PgP
inducer (eg, reduction in anticonvulsant dose); addition
of (or increase in the dose of ) a CYP3A4 or PgP
inhibitor.
Statistical analyses
Approximately, up to 250 patients were planned to be
enrolled based on the expected accrual rates and the
planned duration of the trial. Data were summarized
with respect to demographic and baseline characteristics,
efficacy observations and measurements, safety observa-
tions and measurements. Categorical data were pre-
sented as frequencies and percentages. Final analyses
were performed at the end of the study when all patients
had discontinued everolimus (ie, they were moved to
commercial drug or to local transition plans by Decem-
ber 31, 2013). No formal statistical tests were conducted.
Efficacy population included full analysis set (FAS) de-
fined as patients who received at least one dose of evero-
limus. Safety population consisted of all patients who
received at least one dose of everolimus and had at least
one post-baseline safety assessment. In order to evaluate
the safety data in the pediatric subpopulation, an add-
itional post hoc analysis by age group (< 18 or ≥
18 years) was made. Statistical analyses were done with
SAS software (version 9.3).
Results
Overall results
Overall, 120 patients were enrolled from 44 sites in nine
countries (Fig. 1) between March 28, 2011 and June 30,
2013. Of the 120 patients, 90 (75 %) patients were <
18 years of age (pediatric subpopulation) and 30 (25 %)
patients were ≥ 18 years of age. A total of 100 (83.3 %)
patients of FAS and 79 (87.8 %) of the pediatric subpop-
ulation completed the study (Table 1), which means that
they were either moved to the commercial drug or to
the local transition plan by December 31, 2013. Median
age of patients was 11 years (range, 1–47; one patient
was 1 year old [protocol deviation]) (Table 2).
In addition to SEGA, majority of the patients also had
other major neurological features of TSC including sub-
ependymal nodule (85 %) and cortical tuber (88.3 %).
Fig. 1 Patients enrolled in EFFECTS
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Other major features frequently seen in this population
included hypomelanotic macules (79.2 %), facial angiofi-
bromas or forehead plaques (77.5 %), and renal angio-
myolipoma (49.2 %) (Table 3).
Treatment exposure
Median daily dose of everolimus was 5.82 mg (range,
2.0–11.8 mg), including days of temporary interruption
of the study drug. Median duration of exposure for all
the 120 patients was 56.5 weeks (range, 0.3–130 weeks).
Everolimus was administered to 57.5 % of patients for at
least 48 weeks and 31.7 % for at least 88 weeks.
Safety
Overall, 89 (74.2 %) patients had at least one AE. The
most common AEs were aphthous stomatitis, pyrexia,
bronchitis, and stomatitis (Table 4). Grade 3 and 4 AEs
were reported in 25 (20.8 %) and three (2.5 %) patients,
respectively. The most frequent grade 3 AE was stoma-
titis (4 patients, 3.3 %). All the other AEs of grade 3 or
4 were reported in ≤ 2 patients. Grade 4 AEs included
acute respiratory failure, gastroenteritis, increased
gamma-glutamyltransferase (ƴ-GT), near drowning,
and aspiration pneumonia. Amenorrhea was reported
in three patients (2.5 % of safety population; 12.5 % [3
of 24] of females of childbearing potential). A total of
62 (51.7 %) patients had suspected drug-related AEs
(Table 5) (14 [11.7 %] of grade 3 and 1 [0.8 %] of grade
4). The suspected drug-related AEs reported in ≥ 5 %
of patients were aphthous stomatitis (18 patients,
15 %), stomatitis (9 patients, 7.5 %), pyrexia (8 patients,
6.7 %), and mouth ulceration (6 patients, 5 %).
In the pediatric subpopulation, 67 (74.4 %) patients ex-
perienced AEs (Table 4). Of these, 21 (23.3 %) patients
had grade 3 AEs and 2 (2.2 %) patients had grade 4 AEs.
The most frequent AE (reported in > 2 % of patients) of
grade 3 was stomatitis (4 patients, 4.4 %). All the other
AEs of grade 3 or 4 were reported in one patient each.
Grade 4 AEs included acute respiratory failure, gastro-
enteritis, near drowning, and aspiration pneumonia. A
total of 45 (50 %) patients had suspected drug-related
AEs; those reported in ≥ 5 % of patients were aphthous
Table 1 Patient disposition
n (%) Everolimus
FAS (N = 120)
Everolimus pediatric
subpopulation
(N = 90)
Patients
Completed study 100 (83.3) 79 (87.8)
Discontinued 20 (16.7) 11 (12.2)
Primary reason for premature discontinuation
Adverse event(s) 8 (6.7) a 4 (4.4)
Otherb 5 (4.2) 3 (3.3)
Subject withdrew consent 5 (4.2) 2 (2.2)
Administrative problems 1 (0.8) 1 (1.1)
SEGA progression 1 (0.8) 1 (1.1)
FAS full analysis set, SEGA subependymal giant cell astrocytoma
aIncludes abnormal laboratory values
bIncludes investigator’s decision and mother’s decision
Table 2 Demographic summary
Demographic characteristics Everolimus
N = 120
Age, median (range), years 11.0 (1–47) a
Sex, n (%)
Male 62 (51.7)
Female 58 (48.3)
Race, n (%)
Caucasian 116 (96.7)
Asian 2 (1.7)
Native American 1 (0.8)
Other 1 (0.8)
aone patient was 1 year old (protocol deviation)
Table 3 Disease characteristics
Disease characteristics Everolimus
N = 120
Time since TSC diagnosis, median (range), years 9.1 (0.2–30.7)
Time since SEGA diagnosis, median (range), years 3.8 (0–24)
Modified Gomez criteria - major features, n (%)
Facial angiofibromas or forehead plaques 93 (77.5)
Non-traumatic ungual or periungual fibroma 18 (15.0)
Hypomelanotic macules (3 or more) 95 (79.2)
Shagreen patch (connective tissue nevus) 47 (39.2)
Multiple retinal nodular hamartomas 23 (19.2)
Cortical tuber 106 (88.3)
Subependymal nodule 102 (85.0)
Subependymal giant cell astrocytoma 120 (100.0)
Cardiac rhabdomyoma, single or multiple 55 (45.8)
Lymphangioleiomyomatosis 2 (1.7)
Renal angiomyolipoma 59 (49.2)
Modified Gomez criteria - minor features, n (%)
Multiple, randomly distributed pits in dental enamel 6 (5.0)
Hamartomatous rectal polyps 0 (0.0)
Bone cysts 2 (1.7)
Cerebral white matter radial migration lines 16 (13.3)
Gingival fibromas 6 (5.0)
Non-renal hamartoma 3 (2.5)
Retinal achromic patch 4 (3.3)
'Confetti' skin lesions 15 (12.5)
Multiple renal cysts 19 (15.8)
SEGA subependymal giant cell astrocytoma, TSC tuberous sclerosis complex
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stomatitis (13 patients, 14.4 %), stomatitis (7 patients,
7.8 %), pyrexia (7 patients, 7.8 %), mouth ulceration (5
patients, 5.6 %), and pneumonitis (5 patients, 5.6 %).
Twelve (13.3 %) patients were reported to have sus-
pected drug-related AEs of grade 3; the only suspected
drug-related AE of grade 3 reported in more than one
patient was stomatitis (4 patients, 4.4 %); no patient re-
ported a suspected drug-related AE of grade 4.
Overall, AEs requiring study drug dose adjustment or
interruption were reported in 36 (30 %) patients. Stoma-
titis (6 patients, 5 %), pneumonitis (5 patients, 4.2 %), pyr-
exia (4 patients, 3.3 %), aphthous stomatitis (3 patients,
2.5 %), and bronchitis (3 patients, 2.5 %) were the most
common causes of dose adjustment or interruption. In the
pediatric subpopulation, AEs requiring dose adjustment
or interruption were reported in 27 (30.0 %) patients. The
most commonly reported AEs in these patients were
pneumonitis (5 patients; grade 3 in one patient), stomatitis
(4 patients; grade 3 in two patients), pyrexia (4 patients;
grade 3 in one patient), and bronchitis (3 patients; grade 3
Table 4 Adverse events in > 3 % of patients
AEs, n (%) Safety population
(N = 120)
Pediatric subpopulation
(N = 90)
All Grades Grade 3 or 4 All Grades Grade 3 or 4
Patients with any AE(s) 89 (74.2) 28 (23.3) 67 (74.4) 23 (25.5)
Preferred term
Aphthous stomatitis 18 (15.0) 2 (1.7) 13 (14.4) 1 (1.1)
Pyrexia 18 (15.0) 1 (0.8) 16 (17.8) 1 (1.1)
Bronchitis 11 (9.2) 1 (0.8) 11 (12.2) 1 (1.1)
Stomatitis 10 (8.3) 4 (3.3) 7 (7.8) 4 (4.4)
Cough 6 (5.0) - 5 (5.6) -
Diarrhea 6 (5.0) 1 (0.8) 5 (5.6) 1 (1.1)
Headache 6 (5.0) 1 (0.8) 3 (3.3) 1 (1.1)
Mouth ulceration 6 (5.0) - 5 (5.6) -
Sinusitis 6 (5.0) 1 (0.8) 6 (6.7) 1 (1.1)
Abdominal pain 5 (4.2) - 3 (3.3) -
Blood creatine phosphokinase increased 5 (4.2) 1 (0.8) 3 (3.3) 1 (1.1)
Gastroenteritis 5 (4.2) 1 (0.8) 4 (4.4) 1 (1.1)
Hypercholesterolemia 5 (4.2) - - -
Pharyngitis 5 (4.2) - 5 (5.6) -
Pneumonia 5 (4.2) - 5 (5.6) -
Pneumonitis 5 (4.2) - 5 (5.6) -
Upper respiratory tract infection 5 (4.2) - 4 (4.4) -
Menstruation irregular 4 (3.3) a - 3 (3.3) -
Nasopharyngitis 4 (3.3) - 4 (4.4) -
Otitis media 4 (3.3) - 4 (4.4) -
Urinary tract infection 4 (3.3) - - -
AE adverse event
aThis percentage includes all patients as the denominator. If we consider the females with child bearing potential (n = 24), 16.6 % of patients reported menstrual
irregular events
Table 5 Deaths, serious adverse events, and adverse events
leading to permanent discontinuation of study drug (safety
population)
AEs, n (%) Everolimus
N = 120
Patients with any AE(s) 89 (74.2)
Death 0 (0.0)
SAE(s) 32 (26.7)
Discontinuation due to AE(s) a 8 (6.7)
AE(s) causing dose adjustment or study drug interruption 36 (30.0)
CTC Grade 3 or 4 28 (23.3)
Leading to hospitalization/prolonged hospitalization 29 (24.2)
Suspected to be drug related 62 (51.7)
AE adverse event, CTC common terminology criteria, SAE serious adverse event
aIncludes abnormal laboratory values
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in one patient). Other events were reported in ≤ 2
patients.
Adverse events leading to hospitalization or prolonged
hospitalization were reported in 29 (24.2 %) patients
(Table 5). Of these, 23 were pediatric patients. Most
commonly reported AEs were pyrexia (in four patients),
bronchitis (in three patients), and gastroenteritis, viral
gastroenteritis, pneumonia, sinusitis, diarrhea, stomatitis,
hydrocephalus, status epilepticus, ovarian cyst (in two
patients each).
Overall, SAEs were reported in 32 (26.7 %) patients.
The most common SAEs were pyrexia (5 patients,
4.2 %) and bronchitis (3 patients, 2.5 %). Other SAEs re-
ported (in > 1 %; two patients each) included diarrhea,
gastroenteritis, viral gastroenteritis, hydrocephalus, ovar-
ian cyst, pneumonia, pneumonitis, sinusitis, status epi-
lepticus, stomatitis, urinary tract infection, and vomiting.
Grade 3 SAEs were reported in 22 (18.3 %) patients and
grade 4 in two (1.6 %) patients. Grade 4 SAEs were acute
respiratory failure, aspiration pneumonia, and near
drowning in one patient; gastroenteritis in the second
patient.
Adverse events leading to study drug discontinuation
were reported in eight (6.7 %) patients; four of them
were pediatric patients. These AEs included increase in
-GT (in two patients) and decreased white blood cell
count, atrioventricular block, stomatitis, headache,
hydrocephalus, somnolence, ovarian cyst, and respiratory
tract inflammation (in one patient each).
Overall, in eight (6.7 %) patients, the hematology la-
boratory values worsened to CTC grade 3. These in-
cluded low absolute neutrophils in six patients (4
patients in pediatric subpopulation), low hemoglobin in
one patient (1 patient in pediatric subpopulation), and
low white blood cells in one patient (none in pediatric
subpopulation). None of the hematology values wors-
ened to CTC grade 4. The biochemistry parameters
most commonly reported with worsening to CTC grade
3 or 4 were low sodium in six patients (3 in pediatric
subpopulation) and high -GT in five patients (2 in
pediatric subpopulation). Two patients in the pediatric
subpopulation had high potassium of grade 3.
No deaths occurred during the study or 28-day post
treatment follow-up period and no significant changes
were reported in vital signs from baseline to end of
treatment.
Efficacy
A partial response was reported in 81 (67.5 %) patients,
a stable disease in 35 (29.2 %) patients, and a progressive
disease in one (0.8 %) patient (Table 6). No patient had a
complete response. The response was unknown in three
(2.5 %) patients; in one patient, MRI was not required as
per protocol because the patient completed the study
before the first planned MRI assessment; in the second
patient, there was a premature discontinuation for head-
ache, hydrocephalus, and drowsiness; in the third patient
MRI was not done, as the patient discontinued prema-
turely due to mother’s decision.
Pharmacokinetics
Mean everolimus trough blood levels were below the
target range of five to 15 ng/mL at week 2 (n = 109;
4.06 ng/mL; SD, 2.873) and at week 4 (n = 87; 4.89 ng/
mL; SD, 2.937). The levels at week 6 (n = 57; 5.01 ng/
mL; SD, 3.171) and at week 8 (n = 65; 5.27 ng/mL; SD,
3.011) were within the target range, although closer to
the lower limit.
Discussion
SEGAs have the potential to grow over time [6]. Active sur-
veillance with neuroimaging is therefore recommended
even for asymptomatic SEGAs. Surgical resection is the
recommended treatment for acutely symptomatic SEGAs
[17, 18]. For growing SEGAs that are asymptomatic, either
surgery or mTOR inhibitors can be considered. Decision
regarding the treatment is usually challenging and made in
consultation with a multidisciplinary team that includes
neurosurgeons, neurologists, neuroradiologists, and neu-
rooncologists [17–19]. mTOR inhibitors have also been
shown to be effective in the treatment of a number of other
manifestations of TSC including renal angiomyolipoma,
lymphangioleiomyomatosis, and epilepsy [20–27]. In pa-
tients with multisystem disease, treatment with mTOR in-
hibitors may therefore be preferred over surgery. The 2012
International TSC Consensus Conference guidelines for the
surveillance and management of TSC recommend mTOR
inhibitors for the patients with multisystem disease as well
as for the patients with multiple or infiltrating tumors that
are not amenable to surgical resection [18]. mTOR inhibi-
tors may also be considered for shrinkage of a large tumor
prior to surgical resection [28, 29].
EFFECTS sought to evaluate the safety and efficacy of
everolimus for the treatment of patients with SEGA as-
sociated with TSC in a real-world setting. This expanded
access program was initiated in 2011 to address an un-
met need and make everolimus accessible to patients
with SEGA associated with TSC, in countries where it
Table 6 Investigator assessed best overall response
Best response according to medical judgment Everolimus
(N = 120), n (%)
Complete response 0 (0.0)
Partial response 81 (67.5)
Stable disease 35 (29.2)
Progressive disease 1 (0.8)
Unknown 3 (2.5)
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was not yet commercially available. The inclusion cri-
teria were specifically designed to enable maximum
number of patients to participate and were therefore less
restrictive than those for the open-label phase 1–2 study
or the phase 3 EXIST-1 study. For example, diagnosis
and follow-up of SEGA by either MRI or CT scan were
allowed in this study.
The baseline characteristics of the disease observed in
this study demonstrate the multisystem involvement in
TSC. Majority of patients with SEGA also had other
manifestations of TSC including other brain lesions
(subependymal nodules and cortical tubers) and skin
lesions (facial angiofibroma, forehead plaques, and hypo-
melanotic macules). In addition, renal angiomyolipomas
were also seen in almost a half of the patients. It is im-
portant to note that modified Gomez criteria (1998) was
used for the clinical diagnosis of TSC as the patient re-
cruitment preceded the recommendations of the 2012
International TSC Consensus Conference.
The results of this expanded access program are com-
parable to the findings from previous studies of everoli-
mus in SEGA associated with TSC. The AEs observed
during this study were consistent with the known safety
profile of everolimus in TSC [10, 11, 20, 30, 31]. Most
AEs were of grade 1 or 2, and were manageable; no new
safety concerns were identified. Aphthous stomatitis and
infections continued to be the most common AEs as
seen in the previous studies of everolimus treatment in
TSC. In addition, the AEs observed in FAS and pediatric
subpopulation appeared to be similar. Patients discon-
tinuing due to drug-related AEs were a few. Interest-
ingly, grade 3 or 4 AEs (23.3 %) appeared to be less
frequent when compared to the phase 1–2 study where
they were observed in 39 % of the patients [10]. In the
EXIST-1 study, 33 % of the patients in the everolimus
group vs 23 % in the placebo group experienced an AE
of either grade 3 or 4 [11]. In the 2-year extension ana-
lysis, 51 % of the patients were reported to have grade 3
or 4 AEs [30]. The longer term data suggest that AEs
seem to reduce over time and necessitates the need for
an early detection and treatment of AEs [30, 31].
The effect of everolimus on growth and sexual matur-
ation is not yet clear. In this study, of the 24 women
with childbearing potential, three had amenorrhea and
four reported irregular menstruation. While some data
indicate that mTOR inhibition may partly be associated
with the control of puberty onset [32], it has also been
suggested that amenorrhea could be caused by TSC per
se and may not be related to the treatment with mTOR
inhibitors [33]. Following the report of amenorrhea in
three of eight girls in EXIST-1, the protocol was
amended to include long-term assessment of potential
effects of everolimus on growth, development, and sex-
ual maturation in the pediatric population [11]. In the 2-
year extension data of EXIST-1 study, five of 28 women
experienced amenorrhea; four of five cases resolved
spontaneously [30]. In the EXIST-2 study, which evalu-
ated the efficacy and safety of everolimus in the patients
with angiomyolipoma associated with TSC or sporadic
lymphangioleiomyomatosis, seven of 52 women treated
with everolimus reported amenorrhea; four cases re-
solved; none of the patients discontinued treatment [20].
Long-term follow-up of these studies may give a clearer
picture of the effect of everolimus on the reproductive
system, if any.
Clinical benefit (partial response) was seen in majority
(67.5 %) of the patients and a stable disease in about 30 %
of the patients. Only one patient had disease progression.
Moreover, these results were seen at a low normal range
of everolimus blood levels. No conclusions could be
drawn on pharmacokinetic parameters of everolimus as
the blood samples collected in the EFFECTS study was
aimed to maintain the mean everolimus trough blood
levels within the desired range of 5–15 ng/mL. The effi-
cacy of everolimus in TSC-associated SEGA has been
established in previous studies. Efficacy was first demon-
strated in the open-label, phase 1–2 study of 28 patients
with serial growth of SEGA in which everolimus was asso-
ciated with clinically relevant and statistically significant
reduction in primary SEGA volume at 6 months relative
to baseline (P < 0.001) [10]. The long-term extension of
this study demonstrated that everolimus was safe and ef-
fective for up to 3 years in these patients [31]. In the phase
3 EXIST-1 study (117 patients were randomized [2:1] to
receive everolimus [n = 78] or placebo [n = 39]), 35 % of
the patients in the everolimus group showed a minimum
of 50 % reduction in the volume of SEGAs vs none in the
placebo group (P < 0.0001) [11]. The expanded access
data from EFFECTS further support the efficacy and
hence the use of everolimus in patients with SEGA associ-
ated with TSC.
Conclusion
In summary, the results of this expanded access program
confirm the acceptable safety profile of everolimus in pa-
tients < 18 years (pediatric subpopulation) and > 18 years
of age, as shown by the low incidence of SAEs and grade
3 or 4 AEs. Reported events were consistent with the
known safety profile of everolimus and manageable with
the appropriate medical intervention. The results further
support the efficacy of everolimus in the treatment of
SEGA associated with TSC.
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